14 research outputs found
Prophylaxis after Exposure to Coxiella burnetii
Postexposure prophylaxis may avert Q fever illness and death when the probability of exposure is above the population-specific threshold point
Recommended from our members
Urinary tract infections. Roundtable discussion and case studies
1: COMPARATIVE EFFECT OF SELECTIVE AND NON-SELECTIVE COX-2 INHIBITORS ON LIPID ACCUMULATION IN HUMAN MACROPHAGES
Antibody response to a sub-potent influenza vaccine among nursing home residents and results of revaccination, New York, 1996-97
Background: In November 1996,11 lots of 1996-97 trivalent influenza vaccine were recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Since higher antibody liters afford greater protection against influenza and because elderly persons are at high risk of influenza-related complications, we assessed the antibody titers of nursing home residents who received either recalled vaccine (RV) or non-RV. We then assessed the antibody response to revaccination among a subgroup of residents who had first received RV. Methods: We studied 86 residents from 3 nursing homes who received RV and 86 from 3 other nursing homes who received non-RV. Medical records were reviewed and blood samples were obtained 3 weeks after vaccination. Serum was tested by hemagglutination inhibition (HI) for antibody to all 3 components of the 1996-97 influenza vaccine. Sera collected from 23 residents from one nursing home before and 3 weeks after revaccination with normal potency vaccine were also tested by HI. Results: The geometric mean antibody titer (GMT) (33 vs. 55; p =0.01) and the percentage of residents with an antibody tiler >1:40 (52% vs. 67%; p = 0.04) to the A/Nanchang component were lower among residents who received RV than among residents who received non-RV. In the 23 residents assessed for response to revaccination, GMT to the A/Nanchang component increased from 24 to 39 (p=0.01) after revaccination. Conclusions: Residents who received RV had lower post-vaccination antibody titers to A/Nanchang than did those who received non-RV. Revaccination of residents who first received RV was associated with a rise in titer to the A/Nanchang component.Link_to_subscribed_fulltex
Phase II Trial of Docetaxel, Cisplatin, Fluorouracil, and Leucovorin as Induction for Squamous Cell Carcinoma of the Head and Neck
Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996-97
In November 1996, 11 lots of one U.S. manufacturer's 1996-97 trivalent influenza vaccine were voluntarily recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Because the elderly are at high risk of developing influenza-related complications, we assessed the postvaccination antibody titers of nursing home residents who received recalled vaccine and assessed the antibody response to revaccination. Blood samples were collected 3 weeks after vaccination from 86 residents at three nursing homes who received recalled vaccine and 86 residents at three other nursing homes who received a different manufacturer's vaccine. Medical records were reviewed. Residents of one nursing home were later revaccinated. Blood samples were collected on the day of revaccination and again in 3 weeks. Serum was tested by hemagglutination inhibition for antibody to all three components of the 1996-97 influenza vaccine. The geometric mean antibody titer (GMT) (33 vs 55; p = 0.01) and the percentage of residents with an antibody titer ≥1:40 (52 vs 67%; p = 0.04) to the A/Nanchang/933/95 component were lower among residents who received recalled vaccine compared to those who received non-recalled vaccine, but had similar GMTs against the other two vaccine components. After revaccination, the GMT to A/Nanchang/933/95 increased from 24 on the day of revaccination to 39 (p = 0.01) in residents from one nursing home. Therefore, vaccination with the recalled vaccine was associated with lower postvaccination antibody titers to A/Nanchang/933/95, but not against the other two vaccine components. Revaccination was moderately effective in increasing antibody titers. With annual changes in influenza vaccine strains, routine post-release stability testing of influenza vaccine should continue.Link_to_subscribed_fulltex